NO309039B1 - Polymorfer av pro-legemidlet 6-N-(L-ALA-L-ALA)-trovafloxacin - Google Patents
Polymorfer av pro-legemidlet 6-N-(L-ALA-L-ALA)-trovafloxacin Download PDFInfo
- Publication number
- NO309039B1 NO309039B1 NO980863A NO980863A NO309039B1 NO 309039 B1 NO309039 B1 NO 309039B1 NO 980863 A NO980863 A NO 980863A NO 980863 A NO980863 A NO 980863A NO 309039 B1 NO309039 B1 NO 309039B1
- Authority
- NO
- Norway
- Prior art keywords
- pii
- polymorph
- diffraction pattern
- water
- pro
- Prior art date
Links
- 239000000651 prodrug Substances 0.000 title claims description 19
- 229940002612 prodrug Drugs 0.000 title claims description 19
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 29
- 238000000034 method Methods 0.000 claims description 19
- 150000004682 monohydrates Chemical class 0.000 claims description 19
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 18
- 238000002441 X-ray diffraction Methods 0.000 claims description 14
- 150000001875 compounds Chemical class 0.000 claims description 13
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical group CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 12
- WVPSKSLAZQPAKQ-CDMJZVDBSA-N trovafloxacin Chemical compound C([C@H]1[C@@H]([C@H]1C1)N)N1C(C(=CC=1C(=O)C(C(O)=O)=C2)F)=NC=1N2C1=CC=C(F)C=C1F WVPSKSLAZQPAKQ-CDMJZVDBSA-N 0.000 claims description 11
- 229960000497 trovafloxacin Drugs 0.000 claims description 11
- 208000035143 Bacterial infection Diseases 0.000 claims description 7
- 239000003960 organic solvent Substances 0.000 claims description 7
- 238000000634 powder X-ray diffraction Methods 0.000 claims description 7
- 239000002904 solvent Substances 0.000 claims description 7
- 208000022362 bacterial infectious disease Diseases 0.000 claims description 6
- 238000001291 vacuum drying Methods 0.000 claims description 5
- 241000124008 Mammalia Species 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 239000002253 acid Substances 0.000 claims description 3
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- 150000007513 acids Chemical class 0.000 claims description 2
- 125000005907 alkyl ester group Chemical group 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 125000006724 (C1-C5) alkyl ester group Chemical group 0.000 claims 1
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 12
- 239000013078 crystal Substances 0.000 description 12
- 239000002002 slurry Substances 0.000 description 12
- 239000011541 reaction mixture Substances 0.000 description 10
- 238000010992 reflux Methods 0.000 description 9
- 238000001914 filtration Methods 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- BZNDDHWTEVCBAD-BQBZGAKWSA-N (2s)-2-[[(2s)-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoyl]amino]propanoic acid Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)OC(C)(C)C BZNDDHWTEVCBAD-BQBZGAKWSA-N 0.000 description 2
- GKQLYSROISKDLL-UHFFFAOYSA-N EEDQ Chemical compound C1=CC=C2N(C(=O)OCC)C(OCC)C=CC2=C1 GKQLYSROISKDLL-UHFFFAOYSA-N 0.000 description 2
- -1 L- alaninamide- methanesulfonate Chemical compound 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 229940098779 methanesulfonic acid Drugs 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 238000010533 azeotropic distillation Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Steroid Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US510995P | 1995-08-29 | 1995-08-29 | |
| PCT/IB1996/000653 WO1997008191A1 (en) | 1995-08-29 | 1996-07-05 | Polymorphs of the prodrug 6-n-(l-ala-l-ala)-trovafloxacin |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO980863D0 NO980863D0 (no) | 1998-02-27 |
| NO980863L NO980863L (no) | 1998-02-27 |
| NO309039B1 true NO309039B1 (no) | 2000-12-04 |
Family
ID=21714229
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO980863A NO309039B1 (no) | 1995-08-29 | 1998-02-27 | Polymorfer av pro-legemidlet 6-N-(L-ALA-L-ALA)-trovafloxacin |
Country Status (35)
| Country | Link |
|---|---|
| US (1) | US6080756A (cs) |
| EP (1) | EP0847400B1 (cs) |
| JP (1) | JPH11509188A (cs) |
| KR (1) | KR100274736B1 (cs) |
| CN (1) | CN1193977A (cs) |
| AP (1) | AP639A (cs) |
| AR (1) | AR004507A1 (cs) |
| AT (1) | ATE208790T1 (cs) |
| AU (1) | AU696414B2 (cs) |
| BR (1) | BR9610283A (cs) |
| CA (1) | CA2230303C (cs) |
| CO (1) | CO4480740A1 (cs) |
| CZ (1) | CZ291524B6 (cs) |
| DE (1) | DE69617027T2 (cs) |
| DK (1) | DK0847400T3 (cs) |
| DZ (1) | DZ2088A1 (cs) |
| ES (1) | ES2164892T3 (cs) |
| GT (1) | GT199600061A (cs) |
| HR (1) | HRP960396A2 (cs) |
| HU (1) | HUP9900226A3 (cs) |
| IL (1) | IL122652A (cs) |
| MA (1) | MA23965A1 (cs) |
| NO (1) | NO309039B1 (cs) |
| NZ (1) | NZ310542A (cs) |
| OA (1) | OA10670A (cs) |
| PL (1) | PL185709B1 (cs) |
| PT (1) | PT847400E (cs) |
| RU (1) | RU2151152C1 (cs) |
| SK (1) | SK283354B6 (cs) |
| TN (1) | TNSN96110A1 (cs) |
| TR (1) | TR199800340T1 (cs) |
| UA (1) | UA48982C2 (cs) |
| WO (1) | WO1997008191A1 (cs) |
| YU (1) | YU48296A (cs) |
| ZA (1) | ZA967281B (cs) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HN1998000106A (es) | 1997-08-01 | 1999-01-08 | Pfizer Prod Inc | Composiciones parenterales de alatroflaxacino |
| US6239141B1 (en) * | 1999-06-04 | 2001-05-29 | Pfizer Inc. | Trovafloxacin oral suspensions |
| CN105510497A (zh) * | 2015-11-30 | 2016-04-20 | 精晶药业股份有限公司 | L-丙氨酰-l-丙氨酸的定量检测方法 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5164402A (en) * | 1989-08-16 | 1992-11-17 | Pfizer Inc | Azabicyclo quinolone and naphthyridinone carboxylic acids |
-
1996
- 1996-07-05 JP JP9504021A patent/JPH11509188A/ja active Pending
- 1996-07-05 PT PT96918806T patent/PT847400E/pt unknown
- 1996-07-05 AU AU61351/96A patent/AU696414B2/en not_active Ceased
- 1996-07-05 WO PCT/IB1996/000653 patent/WO1997008191A1/en active IP Right Grant
- 1996-07-05 UA UA98021016A patent/UA48982C2/uk unknown
- 1996-07-05 CN CN96196577A patent/CN1193977A/zh active Pending
- 1996-07-05 KR KR1019980701467A patent/KR100274736B1/ko not_active IP Right Cessation
- 1996-07-05 RU RU98103462/04A patent/RU2151152C1/ru not_active IP Right Cessation
- 1996-07-05 DK DK96918806T patent/DK0847400T3/da active
- 1996-07-05 CZ CZ1998552A patent/CZ291524B6/cs not_active IP Right Cessation
- 1996-07-05 BR BR9610283A patent/BR9610283A/pt not_active Application Discontinuation
- 1996-07-05 HU HU9900226A patent/HUP9900226A3/hu unknown
- 1996-07-05 AT AT96918806T patent/ATE208790T1/de not_active IP Right Cessation
- 1996-07-05 NZ NZ310542A patent/NZ310542A/en unknown
- 1996-07-05 ES ES96918806T patent/ES2164892T3/es not_active Expired - Lifetime
- 1996-07-05 TR TR1998/00340T patent/TR199800340T1/xx unknown
- 1996-07-05 IL IL12265296A patent/IL122652A/xx not_active IP Right Cessation
- 1996-07-05 CA CA002230303A patent/CA2230303C/en not_active Expired - Fee Related
- 1996-07-05 DE DE69617027T patent/DE69617027T2/de not_active Expired - Fee Related
- 1996-07-05 SK SK237-98A patent/SK283354B6/sk unknown
- 1996-07-05 PL PL96325203A patent/PL185709B1/pl unknown
- 1996-07-05 EP EP96918806A patent/EP0847400B1/en not_active Expired - Lifetime
- 1996-07-05 US US09/011,370 patent/US6080756A/en not_active Expired - Fee Related
- 1996-08-09 GT GT199600061A patent/GT199600061A/es unknown
- 1996-08-23 AR ARP960104085A patent/AR004507A1/es unknown
- 1996-08-28 ZA ZA9607281A patent/ZA967281B/xx unknown
- 1996-08-28 MA MA24343A patent/MA23965A1/fr unknown
- 1996-08-28 DZ DZ960132A patent/DZ2088A1/fr active
- 1996-08-28 YU YU48296A patent/YU48296A/sh unknown
- 1996-08-28 TN TNTNSN96110A patent/TNSN96110A1/fr unknown
- 1996-08-29 HR HR60/005,109A patent/HRP960396A2/hr not_active Application Discontinuation
- 1996-08-29 CO CO96046150A patent/CO4480740A1/es unknown
- 1996-08-29 AP APAP/P/1996/000854A patent/AP639A/en active
-
1998
- 1998-02-27 OA OA9800027A patent/OA10670A/en unknown
- 1998-02-27 NO NO980863A patent/NO309039B1/no unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5763454A (en) | Crystal form of anhydrous 7-( 1α,5α,6α!-6-amino-3-azabicyclo 3.1.0!hex-3-yl)-6-fluoro-1-(2,4-difluorophenyl)-1,4-dihydro-4-oxo-1,8 naphthyridine-3-carboxylic acid, methanessulfonic acid salt | |
| CN113766916B (zh) | Mtorc调节剂及其用途 | |
| BG104105A (bg) | Алатрофлоксацинови парентерални състави | |
| NO309039B1 (no) | Polymorfer av pro-legemidlet 6-N-(L-ALA-L-ALA)-trovafloxacin | |
| RU2144921C1 (ru) | Кристаллическая форма цвиттериона тровафлоксацина и способ ее получения | |
| US6066647A (en) | Zwitterionic forms of trovafloxacin | |
| AP788A (en) | Novel crystal form of anhydrous 7-(1a, 5a, 6a)-6-Amino-3-Azabicyclo(3.1.0) hex-3-YI)-6-Fluoro-1-(2,4- Difluorophenyl)-1,4-Dihydro-4-Oxo-1, 8-Naphthyridine-3-Carboxylic Acid, Methanesulfonic acid salt. |